

Non-Mucosal


Differentiated
thyroid cancer

[END0021](#)
[Phase III](#)
[Cabozantinib](#)
[\(XL184\) in](#)
[Radioiodine-](#)
[Refractory](#)
[Differentiated](#)
[Thyroid Cancer](#)

PI: Colevas
Sponsor: Exelixis

KEY

 Pending

 Open for Enrollment


 Observational Study

-> Optional Path

[Link](#) Trial Posting

 Enrollment on Hold

 Extension Study

 Immunotherapy